Pedro Fonseca, MD, Coimbra Hospital and University Centre, Portugal, and Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist, Texas, USA, discuss the various pros and cons of offering teprotumumab for all patients with thyroid eye disease.
Martin David Harp
Advertisement
Articles by Martin David Harp
Advertisement
Advertisement
Advertisement
Trending on Modern Retina
1
FDA grants RMAT designation to RTx-015 optogenetic gene therapy for retinitis pigmentosa
2
Directional OCT provides biomarkers of Parkinson’s Disease in the outer retina
3
Merck launches phase 2b/3 MALBEC trial of MK-8748 in wet AMD
4